

Jose U Scher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2908716/jose-u-scher-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

5,664
citations

35
h-index

75
g-index

102
ext. papers

7,338
ext. citations

8.6
avg, IF

6.16
L-index

#	Paper	IF	Citations
84	Does biologic therapy impact the development of PSA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
83	A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	4
82	Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. <i>Cell Host and Microbe</i> , 2021 , 29, 362-377.e11	23.4	24
81	Another SEES - Brain-Eye-Ear (BEE) Disease Secondary to HbSC Disease Masquerading as Multiple Sclerosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105618	2.8	
80	Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease 2021 ,		12
79	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
78	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1339-1344	2.4	78
77	Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. <i>Blood</i> , 2021 , 138, 1456-1464	2.2	4
76	Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data. <i>Nature Biotechnology</i> , 2021 , 39, 169-173	44.5	36
75	Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 809-815	4.5	3
74	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 913-920	4.5	6
73	Key opinion leaders - a critical perspective. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 119-124	8.1	10
72	The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 931-942	9.5	28
71	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. <i>Rheumatology</i> , 2021 , 60, 2307-2316	3.9	2
70	Induction of remission in biologic-naive, severe psoriasis and PSA with dual anti-cytokine combination. <i>Rheumatology</i> , 2021 , 60, e225-e226	3.9	1
69	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 238-243	8.1	6
68	Microbial-derived antigens and metabolites in spondyloarthritis. <i>Seminars in Immunopathology</i> , 2021 , 43, 163-172	12	4

67	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021 ,	4.1	2
66	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1574-1578	9.5	
65	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 59	51.1	6
64	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology, The</i> , 2021 , 3, e585-e594	14.2	11
63	Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	39
62	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2112-2122.e34	4.3	2
61	Not your average joint: Towards precision medicine in psoriatic arthritis. <i>Clinical Immunology</i> , 2020 , 217, 108470	9	2
60	Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 282-292	8.1	35
59	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 1340-1351	9.4	23
58	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	40	65
57	Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. <i>New England Journal of Medicine</i> , 2020 , 383, 85-88	59.2	278
56	The microbiome in rheumatology: Where are we and where should we go?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 727-733	2.4	33
55	Interleukin 1 receptor antagonist () gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 400-407	2.4	16
54	KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3151-3157	15.9	16
53	Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation. <i>Arthritis and Rheumatology</i> , 2020 , 72, 645-657	9.5	29
52	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1971-1980	9.5	35
51	COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1981-1989	9.5	66
50	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020 , 22, 78	4.9	6

49	Response to: Microbiome in Sjögren's syndrome: here we are Sby van der Meulen. <i>Annals of the Rheumatic Diseases</i> , 2020 ,		2.4
48	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
47	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. <i>Journal of Rheumatology</i> , 2020 , 47, 1496-1505	4.1	9
46	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 787-798	9.4	33
45	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 153-166	8.1	111
44	Distinct Polysaccharide Utilization Profiles of Human Intestinal Prevotella copri Isolates. <i>Cell Host and Microbe</i> , 2019 , 26, 680-690.e5	23.4	53
43	Microbiome and Microbiota in Rheumatic Disease 2019 , 11-19		
42	OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NATIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY 2019 ,		4
41	Strategies to Improve Outcomes in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2019 , 21, 72	4.9	13
40	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 31-58	1.1	6
39	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 5-32	9.5	178
38	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 2-29	4.7	137
37	Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Enteseal Inflammation in a Novel Model of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 855-867	9.5	18
36	The role of the gut microbiome in systemic inflammatory disease. <i>BMJ, The</i> , 2018 , 360, j5145	5.9	202
35	Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 242-254	9.5	57
34	The Microbiome in Psoriasis and Psoriatic Arthritis: Joints. <i>Journal of Rheumatology</i> , 2018 , 94, 32-35	4.1	11
33	Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. <i>Clinical Rheumatology</i> , 2018 , 37, 415-422	3.9	7
32	Microbiota-Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1971-1983	9.5	26

31	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017 , 44, 693-694	4.1	22
30	Human microbiome, infections, and rheumatic disease. <i>Clinical Rheumatology</i> , 2017 , 36, 2645-2653	3.9	18
29	Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. <i>Scientific Reports</i> , 2017 , 7, 15613	4.9	59
28	Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis. <i>Microbiome</i> , 2017 , 5, 63	16.6	42
27	Short- and long-term effects of oral vancomycin on the human intestinal microbiota. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 128-136	5.1	159
26	The lung microbiota in early rheumatoid arthritis and autoimmunity. <i>Microbiome</i> , 2016 , 4, 60	16.6	108
25	Periodontal Infections and Rheumatoid Arthritis 2016 , 107-115		
24	The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 446-55	8.1	85
23	Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 391-402	3.9	41
22	Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. <i>Arthritis and Rheumatology</i> , 2016 , 68, 35-45	9.5	143
21	Reply: To PMID 25319745. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2280-2	9.5	
20	Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. <i>Arthritis and Rheumatology</i> , 2015 , 67, 128-39	9.5	434
19	Spondyloarthritis and the microbiome: new insights from an ancient hypothesis. <i>Current Rheumatology Reports</i> , 2015 , 17, 10	4.9	12
18	The microbiome in rheumatic diseases 2015 , 145-151		
17	Biomarkers in psoriatic arthritis: recent progress. <i>Current Rheumatology Reports</i> , 2014 , 16, 453	4.9	19
16	Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 317-8	2.4	17
15	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 16814-9	11.5	123
14	Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 101-7	5.3	146

13	Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors?. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 424-9	5.3	64
12	Expansion of intestinal <i>Prevotella copri</i> correlates with enhanced susceptibility to arthritis. <i>ELife</i> , 2013 , 2, e01202	8.9	1092
11	Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3083-94		317
10	B-cell therapies for rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012 , 70, 200-3		15
9	The microbiome and rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 569-78	8.1	303
8	The anti-inflammatory effects of prostaglandins. <i>Journal of Investigative Medicine</i> , 2009 , 57, 703-8	2.9	152
7	Nitric oxide synthases and osteoarthritis. <i>Current Rheumatology Reports</i> , 2007 , 9, 9-15	4.9	60
6	<i>Helicobacter pylori</i> stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activation. <i>Journal of Biological Chemistry</i> , 2007 , 282, 18722-31	5.4	50
5	15d-PGJ2: the anti-inflammatory prostaglandin?. <i>Clinical Immunology</i> , 2005 , 114, 100-9	9	260
4	Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs. <i>Journal of Biological Chemistry</i> , 2005 , 280, 9973-9	5.4	37
3	Neutrophils 139-48		
2	Perturbation of the human gut microbiome by a non-antibiotic drug contributes to the resolution of autoimmune disease		7
1	Distinct polysaccharide growth profiles of human intestinal <i>Prevotella copri</i> isolates		1